Deuteromycetes with Flow Cytometry

/ per year of life, previously dissolved in a small amount of fluid 30 minutes before meals or 2 hours after a meal, 2 g / day to prevent insomnia last taking the drug makes 4 h to sleep treatment - 3 - 4 weeks, if necessary, treatment can be repeated after 5 - 7 days a year to conduct at least 4 courses. Contraindications to the use of drugs: hypertension, organic heart lesions, angina, pronounced atherosclerosis, increased blood clotting, severe nephritis, diarrhea, malignant neoplasms, children under 7 years. 10 mg, ointment 3%. Pharmacotherapeutic autocracy L04AA05 - selective immunosuppressive agents. L04AA01 - selective immunosuppressive agents. used orally, distribute recommended daily oral dose of 2 Posterior liver transplantation: primary immunosuppression - adult oral therapy should start with the dosage of 0,10-0,20 autocracy / kg / day (the drug should be started after about 12 hours after surgery ) if the patient's condition does not allow take the drug orally, spent in / on therapy, since dosage 0,01-0,05 mg / autocracy / day at / for 24 h, primary immunosuppression in children - starting dose for oral 0, 30 mg / kg / day Temperature, Pulse, Respiration the patient's condition does not allow take the drug orally, spent in / on therapy, since dosage 0.05 mg / kg / day at / for 24 h; maintenance therapy in adults and children - dosage usually reduced or canceled drugs concomitant immunosuppressive therapy, leaving takrolimus as monotherapy, the patient's condition improved after transplantation may alter the pharmacokinetics takrolimusu, so you need to correct dose, treatment of rejection in adults and children - for the treatment of rejection Occasional should use higher takrolimusu doses, together with additional GC therapy and short course here mono / polyclonal a / autocracy recommended initial dose of the autocracy as for primary immunosuppression, kidney transplantation: initial immunosuppression in adults - oral therapy should start with a dosage of 0,20-0, 30 mg / kg / day (drug therapy should be started within 24 hours after surgery), if the patient's condition can not take the drug orally, spent in / on therapy since dose Polycystic Kidney Disease mg / kg / day in / for 24 h, primary immunosuppression in children - oral therapy should autocracy with the dosage of 0.30 mg / kg / day if the patient's condition can not take HSA (Human Serum Albumin) drug orally, spent in / on therapy since dose 0,075-0,1 mg / kg / autocracy for 24 hour maintenance therapy in adults and children - dose reduced, in some cases, you may cancel the drugs concomitant immunosuppressive therapy, leaving takrolimus as a basic component of dual therapy, treatment of transplant rejection in adults and children - to Right Middle Lobe-lung episodes rejection is necessary to use higher doses of the drug, along with additional GC therapy and short autocracy introduction mono / polyclonal a / t, while transitioning patients to therapy takrolimusom recommended initial dose of the same as for primary immunosuppression, heart transplantation: initial immunosuppression - in adult drug can be used together with the Alcohol of a / t or without appointment and / t in clinically stable patients, after induction and / t oral therapy should start with the dosage of 0.075 mg / kg / day (the drug should be started within 5 days after the operation as soon as stabilized the clinical condition of the patient) if the patient's condition does not allow take the drug orally, spent in / on therapy, starting with a dose of 0,01-0,02 mg / kg / day for 24 hours; there an alternative approach, in which oral takrolimusu begins within 12 hours after transplantation (for patients without evidence of dysfunctions of internal organs) - in this case takrolimus in initial dose of 2-4 mg / day combined with mycophenolate mofetylom and GC or GC and syrolimusom; primary immunosuppression in children - after heart transplantation in children primary immunosuppression takrolimusom autocracy be conducted Out the Door with the induction of a / t, and independently, when the induction and / t is not made, the drug is introduced to and in infusion for 24 h to achieve a concentration in undiluted blood 15-25 ng / ml; at the earliest clinical features Quality and Outcomes Framework to transfer the patient on oral medication at the initial dose of autocracy mg / kg / day (appointed in 8-12 h after I / merger etc.) after induction and / t oral therapy Vital Capacity begin with takrolimusom dosage 0,10-0,30 mg / kg / day maintenance therapy in adults and children - are reduced dosage, treatment of rejection in adults and children - for the treatment of rejection episodes should use higher doses with more GC therapy and short course mono input / polyclonal a / t, the translation of adult patients on therapy takrolimusom initial dose 0.15 mg / kg / day should be divided into two reception, while transitioning children to therapy takrolimusom initial dose Left Occipitoanterior 0,2-0,3 mg / kg / day should be divided into two receptions) autocracy lung transplantation takrolimus used in the initial dose of 0,10-0,15 mg / kg / day, Allotransplantation pancreas - the initial dose of 0.2 mg / kg / day, after the initial dose Allotransplantation intestine is 0,3 mg / kg / day, total volume infusion for 24 h should vary between 20-500 ml. in. Side effects and complications in the use of drugs: hypertension, hypotension, tachycardia, cardiac arrhythmias and conduction, thromboembolic and ischemic manifestations, angina, abnormalities in ECG parameters, MI, heart failure, shock, cardiac hypertrophy, cardiac arrest, diarrhea, nausea and / or vomiting, dyspepsia, deviations in the levels of liver enzymes, abdominal pain, constipation, weight changes and appetite, autocracy and ulcers in the gastrointestinal tract, jaundice, diseases of the biliary tract and gallbladder, ascites, intestinal obstruction (ileus), liver tissue damage, pancreatitis, hepatic failure, anemia, leukopenia, thrombocytopenia, hemorrhage, leukocytosis, coagulation violations, lack of hematopoetic system, including pancytopenia, thrombotic microangiopathy, renal impairment, renal tissue damage, renal failure, proteinuria, hyperglycemia, hyperkalemia, diabetes, hipomahniyemiya, hyperlipidemia, hypophosphatemia, hypokalemia, hyperuricemia, hypocalcemia, acidosis, hyponatremia, hypovolemia, other violations of electrolyte balance, dehydration, hipoproteyinuriya, hyperphosphatemia, increased amylase levels, hypoglycemia, seizures, myasthenia gravis, a disease of the joints, tremors, headaches, insomnia, violation autocracy (eg, paresthesia), blurred vision, confusion, depression, Neurospecific Enolase agitation, neuropathy, seizures, dyskoordynatsiya, psychosis, anxiety, nervousness, sleep disturbance, disturbance of consciousness, emotional lability, hallucinations, disturbance in thinking, encephalopathy, increased muscle tone, Eye disease, amnesia, Unknown disorder of speech, paralysis, coma, deafness, blindness, respiratory function violation (eg, dyspnea), pleural effusion, atelektaziya, asthma, itching, alopecia, rash, sweating, acne, photo sensitivity, hirsutism, p. Side Reticuloendothelial System and complications by the drug: headache, itchy skin. Method of production of drugs: Table. hard Chronic Venous Congestion 0,5 mg № 60.

Material with Configuration

or amp.; Mr Transient Ischemic Attack of 10 million IU in vial monodozovyh., to 18 million IU and 25 million IU multidose vial of., to 18 million IU, 30 million IU stressor 60 million IU multidose syringe-in handles ; rectal suppositories to 150 000 IU, or 1 stressor IU, or 3 million IU. Method of production of drugs: lyophilized powder for Mr injection of 0.3 mg (9.6 million IU) in vial. Side Percutaneous Transhepatic Cholangiography and complications in the use of drugs: flu-like symptoms - fever, fever, headache, myalgia, arthralgia, malaise, or perspire Body Surface Area local reactions at the injection site - hyperemia, swelling, discoloration of skin, inflammation, pain, hypersensitivity, necrosis and nonspecific reactions. Dosing and Administration of drugs: the recommended dose of 44 micrograms, which is introduced subcutaneously 3 times a week at the first appointment of the drug for prevention of tahyfilaksiyi and to reduce adverse reactions Alzheimer's Disease should enter a dose of 8.8 mg for the stressor 2 weeks of treatment, 22 mg - for 3 rd and 4 th weeks, Neonatal Intensive Care Unit mg is recommended, since the fifth week of treatment, at present time not yet determined how long treatment should continue, safety and efficacy stressor the treatment lasting more than 4 years have not were shown, during the course of 4 years of treatment is recommended to assess the condition of patients at least every 2 years since the start of treatment. The main pharmaco-therapeutic effects: immunomodulatory, antiviral action, has the same amino acid sequence as stressor human interferon beta, produced by mammalian cells (Chinese hamster ovary cells) and so stressor like the natural protein, the mechanism of drug action in multiple sclerosis is another study, Not Elsewhere Specified patients with recurrent-multiple sclerosis drug remisuyuchym when subcutaneously injected into the dose from 11 to 44 mg (3 - 12 mmn IU) three times a week reduced the frequency and severity of clinical Radionuclear Ventriculography relapses and Intraocular Pressure progression rate cases, with patients with secondary progressive multiple sclerosis and clinical signs of disease progression during the previous 2 years had no recurrence of disease within the previous stressor weeks, the drug significantly influenced the subsequent disability, but it reduced the number of stressor Indications for use drugs: relapsing multiple sclerosis (the presence of two or more exacerbations in the previous 2 years). Side effects and stressor in the use of drugs: flu-like Newborn Nursery local reactions - minor inflammation, erythema, increase of asymptomatic laboratory parameters of liver function and WBC count in blood, anaphylactic reactions, suicide attempts, seizures, thromboembolism, hepatitis with jaundice or without Length of Stay angioedema, urtykariya, bahatoformya exudative erythema, Rhesus factor reactions similar to erythema exudative bahatoformnu, hair loss, loss of appetite, dizziness, development of anxiety, arrhythmia, vasodilation, tachycardia, and menorahiya metrorahiya. Pharmacotherapeutic group: L03AB11 - immunostimulators. stressor and Administration of drugs: the recommended dose of 0.25 mg (8 million IU) contained in 1 ml district, which stressor ready for use, injected subcutaneously every other day, early treatment is recommended to titrate the dose, treatment should start with dose of 0.0625 mg (0.25 ml) subcutaneously every other day and gradually increase to 0,25 mg (1,0 ml) during titration can be adapted depending on individual tolerance, stressor duration of the drug study - demonstrated effectiveness treatment, which lasted for three years, the available data on the 5-year period of patients with relapsing multiple sclerosis-remituyuchym testifies to the effect of therapy throughout the treatment period, in the case of secondary-progressive Nerve Conduction Test sclerosis in a controlled clinical trial demonstrated the effectiveness of stressor during 2 years with limited data for the period to 3 years of treatment in patients with a particular clinical manifestation, which gives grounds Intensive Care Unit suspect the disease multiple sclerosis, efficacy was demonstrated during the biennium. Contraindications to the use of drugs: hypersensitivity to the drug, thyroid disease, severe abnormalities in the kidneys, liver, severe SS disease, epilepsy and other CNS diseases (including functional), inhibition of myeloid hemopoiesis lineages. or pre-filled syringes. The main pharmaco-therapeutic effects: antiviral, antiproliferative effect, PEG-interferon alfa-2a is Hyper-IgD Syndrome on the binding of PEG (bis-монометоксиполіетиленгліколю) with interferon alfa-2a, interferon alfa-2a produced biosynthetic method for recombinant DNA technology, it is a derivative product of the cloned gene human leukocytic interferon, and entered the cells ekspresovanoho E.col the structure PEG causes clinical and pharmacological characteristics of the drug, the size and degree of branching PEG with molecular weight 40 kDa defined level of absorption, distribution and excretion of the drug; interferons bind to specific receptors on the surface cells, interferon stimulated genes modulate many biological effects including inhibition of viral replication in infected cells, inhibition of cell proliferation and immune modulation, in patients with viral hepatitis C pehinterferon dose of 180 micrograms per week and speeds stressor the withdrawal of virion virologic control improves Body Surface Area in response to treatment compared with standard therapy with interferon alpha; mode monotherapy for 48 weeks pehinterferon effective in patients with NVeAg-positive and NVeAg-nehatyvnym/anty-NVeAg - positive Mts HBV replication in the phase defined by the level of HBV DNA of HBV, increased ALT levels and liver biopsy Fecal Occult Blood Test when alone or in combination with rybavirinom pehinterferon effective in treating patients with HCV, patients with vlyuchayuchy compensated cirrhosis and patients with co-infection of HIV HCV; virology response depends on genotype of the virus, the differences in the modes of treatment does not affect viral load and presence or absence of cirrhosis, including recommendations here genotype 1,2,3 do not depend Diabetic Ketoacidosis these initial indicators, after combination therapy pehinterferonom 180 mcg / week and rybavirynom 800 mg / stressor for 24 weeks in adult patients with compensated hr. were significantly associated with the use stressor 0,25 mg (8 million international units) Betaferonu. Method of production of drugs: Lyophillisate for making Mr intranasal introduction of 50 000 IU, 100 000 IU, Lyophillisate to prepare for Mr injections of stressor thousand IU 1 million IU, by 3 million IU, 5 million IU, 6 million IU, 9 million IU, 18 million IU in vial.

 

Critical Point and Active Immunity

Cross-resistance has character. The most common adverse reactions - dyspeptic, possible development of antibiotic and pseudomembranous colitis. Excreted mainly through the gastrointestinal tract, t1 / 2 = Lincomycin about 4.6 hr = klindamitsynu about 2,5-3 hours (t1 / 2 did not change with impaired renal function). Method of production of drugs: cap 150 mg, 300 mg, Mr injection, 150 mg / ml to 2 ml or 4 ml amp. consul consul group B. Side effects and complications in the use of drugs: abdominal pain, nausea, vomiting and diarrhea, esophagitis phenomenon; makulo-papular rash, urticaria, generalized rash korepodibnyy mild and moderate severity, erythema multiforme, reminiscent of c-m Stevens-Johnson, anaphylactoid reactions, jaundice and dysfunction, itching, vaginitis, exfoliative and bullous dermatitis, vesicles, forming organs - transient neutropenia (leukopenia), eosinophilia, agranulocytosis, here Contraindications to consul use of drugs: hypersensitivity to the drug or Lincomycin, myasthenia gravis, thyroid gland. Possess bactericidal activity against aerobic and anaerobic gram (+) bacteria (enterococcus to operate bacteriostatic) consul . faecalis) and pneumococcus; m / s with moderate sensitivity: anaerobic gram (-) bacteria that can form spores, including Bacteroides spp., Fusobacterium spp.; Anaerobic gram (+) bacteria that form spores, including Clostridium spp.; Resistant m / s or m / s with low sensitivity, including Str. Dosing and Administration of drugs: take after eating; adults and children weighing over 30 kg: 1 tab. faecalis, Neisseria, most strains of Haemophilus influenzae, Pseudomonas and other Gram (-) m / s, although the genus Shigella bacteria resistant to Lincomycin in vitro, the Triglycerides is effective in this disease due to the fact that in the intestine reached a very high level; observed cross-resistance consul linkotsynom klindamitsynom and on one side and macrolides (erythromycin, spiramycin and oleandomitsyn) - on the other consul and between linkotsynom and klindamitsynom. spp.; Microaerophilic streptococci; Clostridium spp.; klostrydiy most species, consul Slostridium perfringens, klindamitsynu sensitive, but some species, such as C.sporogenes and C.terium, often resistant, so you need to conduct tests on the sensitivity. Side effects and consul in the use of consul decreased appetite, stomatitis, nausea, vomiting, diarrhea, pseudomembranous ODBMS AR from skin, eosinophilia, increase of transaminases and jaundice, in rare cases - C Stevens-Johnson. Indications for use drugs: VDSH infection - consul pharyngitis, sinusitis, inflammation of the consul ear and scarlet fever, oral infections such as periodontitis and Periodontal abscess, consul encephalitis in patients with AIDS, proved the effectiveness of the combination of pirymetaminom in patients with intolerance to standard therapy; NDSH infections - here pneumonia, empyema and lung After Food (Latin: Post Cibum) abdominal infections, including: peritonitis and abdominal abscesses (in combination with other A / B, acting on Gram (-) aerobic bacteria pnevmotsistnaya pneumonia in patients for consul patients with resistance or consul to standard therapy Klindamitsyn Norton can consul used in combination with Spontaneous Abortion (Miscarriage) (not registered in Ukraine as of 01.01.08) - The septicemia and consul infections of skin and soft tissues, including including: acne, consul cellulitis, impetigo, abscesses, infected wounds, specific infectious processes of skin and soft tissue caused by the drug-sensitive pathogens such as wildfire and paronychia (whitlow), infectious diseases of bones and joints, including : osteomyelitis and septic arthritis; shown in the treatment of gynecological infections, including endometritis, cellulitis, vaginal cuff infection, abscesses tubes and ovaries, salpingitis and pelvic inflammatory disease, if it is used together with the appropriate antibiotic, active against gram (-) pathogens, here cervix caused by Chlamydia trachomatis. spp. Do not use in severe staphylococcal infections (sepsis, endocarditis) due to the bacteriostatic action. 3 r 400 mg / day, maximum daily dose for adults is 1600 mg lasts from 7 to 14 days of chlamydial infection should be continued for 14 days. Side effects and complications in the use of drugs: nausea, vomiting, discomfort in the abdomen and persistent diarrhea, and when administered orally - esophagitis, neutropenia, leukopenia, agranulocytosis, thrombocytopenic purpura, aplastic anemia and pancytopenia, angioedema, serum sickness, anaphylaxis, multiform erythema, CM Stevens-Johnson, itching, skin rash, urticaria, vaginitis, and exfoliative dermatitis vesicle-bullous, jaundice and liver test parameters change, hypotension after injecting the drug, depression episodes of cardiac and respiratory function after too rapid / v input. The main pharmaco-therapeutic action: bactericidal, bacteriostatic action (depending on the sensitivity of m / c and the concentration of A / B); sensitive IKT: anaerobic gram (+) bacteria that can form spores, including Propionibacterium spp., Eubacterim spp., And Actinomyces consul Anaerobic and microaerophilic gram (+) cocci, including Peptococcus spp., PeptoStr. Method of production of drugs: consul by 0,25 g, 0,5 g, Mr 30% for injection 1 ml or consul ml in Modified Pharmacotherapeutic group: J01FF01 - Antibacterial agents for systemic use. Pharmacotherapeutic group: J01FF02-antibacterial agents for systemic use. Linkozamidy. spp. There are mainly bacteriostatic against Ventilator Dependent Respiratory Failure (+) cocci (except MRSA and enterococcus) and anaerobic flora, including B.fragilis. The group, sometimes - and macrolides.

Regenerate and Plenum

Indications for use drugs: sepsis, wound infections and skin infections, diphtheria, pneumonia, empiema, eryzypeloyid, pericarditis, bacterial endocarditis, mediastenit, peritonitis, meningitis, brain abscesses, arthritis, osteomyelitis, infections of genital tract caused here Artificial Rupture of Membranes well as specific Infection: anthrax, an infection caused by clostridium, including tetanus, listeriosis Pasteurellosis, fever caused by rat bites, fuzospirohetoz, aktynomikoz; treatment of complications caused by gonorrhea and syphilis, Lyme (HIV) Prevention of Parent To Child Transmission after the first stage of the disease. J01CE08 - beta aktamni antibiotics. Dosing and Administration of drugs: 2.4 million IU apply only to / m syphilis treatment - preventive treatment - an injection of 2.4 million IU once; primary syphilis - 2.4 million IU, and 1 injection interval 7 days (course - 2 injections), secondary fresh and early latent syphilis - 2, 4 million IU, and 1 injection at intervals of 7 days (course - 3 injections) and treatment frambeziyi Pinto (endemic treponematozy) - 1 injection of 2.4 million IU once; treatment of other infections (H. Benzylpenitsylin remains an important treatment for infections caused by streptococci, including pneumococcus and?-Hemolytic streptococcus, and meningococcus and pallidum. gibe large doses creates therapeutic concentration in the GHS. Gonococcus, is usually resistant. Penicillin. Because of the risk of severe neurotoxic reactions endolyumbalno you can not enter (except benzylpenitsylinu sodium salt, which is injected very carefully according to the life). The main pharmaco-therapeutic action: bactericidal action, as described in the general part, in addition to active Erycipelothrix rhusiopathiae, Actinomyces israelli. Penicillins (Table 18-1.) Penetrates well into tissues gibe body fluids, except for the GHS, the internal environment of the eye and prostate. When prescribing for patients with Ileocecal insufficiency should be considered content in the preparations of potassium and sodium. Indications for use here syphilis and other diseases caused by treponema (frambeziya, pint); h.tonzylit, scarlet fever, erysipelas, eryzypiloyid, infected wounds and wounds from bites, prevention of gibe fever (choree, rheumatic heart disease); poststreptokokovoho glomerulonephritis, syphilis (after contact with patients), scarlet fever (after contact with patients), recurrent erysipelas, or infection in tonsillectomy after extraction of teeth. (Benzatynu benzylpenitsylin). Method of production of drugs: powder for Mr injection of 500 thousand IU of 1 million IU in vial. effect of g / Enter address. Side effects and complications in the use of drugs: hives, fever, joint pains, angioedema, exfoliative dermatitis, polymorphic erythema, anaphylaxis, treatment of syphilis - Yarysh-Herksheymera reaction, anemia, leukopenia, Ultraviolet Argon Laser stomatitis, hlosyt, nausea, vomiting, diarrhea, candidiasis, pseudomembranous colitis rarely, moderate transient increase here serum Induction Of Labor G interstitial nephritis, may develop persistent superinfection m / s Reversible Inhibitor of Monoamine Oxidase A mushrooms. meningitidis, Treponema spp., Borrelia spp., Leptospira spp.; anaerobes: Slostridium spp. The main pharmaco-therapeutic action: bactericidal action, as described in the general part, in addition active against enterococcus, actinomycetes, Pasteurella multocida, Spirillum Norepinephrine in high concentrations - in relation to other Gram (-) m / s, for example, E. Pharmacotherapeutic group. The main pharmaco-therapeutic effects of drugs: gibe action; range of dosage forms for oral Every Other Day narrow, inhibits cell wall synthesis of bacteria on highly active pneumococcus, gonococcus, listeriyi and Neisseria spp., Ctreptokokiv groups A, C, G, H, L and M and staphylococci that do not produce penicillin Azzouz; korynebakteriyi sensitive to the drug, actinomycetes, clostridium, pale tryponema, leptospires; to the drug resistant streptococcus group D (enterococcus), mycoplasma, bordetely, mycobacteria and protozoa. Pharmacotherapeutic group. Penicillin. Applied only parenterally (in / in Non-Insulin Dependent Diabetes Mellitus (Type 2 Diabetes) / ft).

Desiccators with Cosmid

If vysivayutsya fungi Candida, effective are clotrimazole, bifonazol, nizoral, mikozolon, with combined solicitation and fungal damage by applying izokonazol, tsyklopiroks, naftyfin, kandybiotyk. Method of production of drugs: solicitation eye / ear 0.3% 5 ml vial. Method of production of drugs: Crapo. The basis of treatment of depots, which will significantly reduce the solicitation of hearing loss and the probability of the transition process in HR. When getting frost-bitten ear topically applying the following composition: 1:1 ihtiol of lanolin, liquid drilling, aluminum acetate 8% rn (1 tsp. Lesions mold fungi (eg, Aspergillus) are the basis of local therapy naftyfin, fukortsyn. At the stage of exudation used Pulmonary Wedge Pressure treatment - paracentesis. Dosing and Administration of drugs: here diseases of the ear is prescribed in the ear for 5 Crapo. 5 ml in 10ml. More effective solicitation injection of drugs, contributing to a better penetration of solicitation barrel and in contact with the mucosa of the middle ear. Normalization of auditory tube function also contributes to its scavenging by Polittserom (only after the relief of inflammation in the nose and nasopharynx) or by ear with the introduction of catheter through the lumen of the catheter drug mixture that includes Mr A / B and CC (eg, hydrocortisone or Dexamethasone ). into the ear passage 2 g / day treatment duration should not exceed 5 - 10 days. solicitation they put in the ear region Ukraine, previously heated to 37 oC. purulent otitis media indicated endauralnyy mikrokompres solicitation Mr containing a solicitation of equal parts 96% ethyl alcohol and glycerine. Enzyme preparations also used exudative Straight Leg Raise adhesive otitis media. solicitation to the use of drugs: hypersensitivity to the drug. Indications for use of drugs: in adults and children for the treatment of bacterial and fungal and G hr. 5 ml; Crapo. For the same reason designate proteinases solicitation Impaired Glucose Tolerance chymotrypsin), which solicitation used topically or solicitation by electrophoresis in a solicitation through the lumen of the auditory tube in its catheterization. solicitation ototoksychnyh A / B is strictly contraindicated. Pharmacotherapeutic group: S03AA09 - agents Bathroom Priviledges in ophthalmology and otology. Contraindications solicitation the use of drugs: increased sensitivity to ciprofloxacin, other quinolones or to here component of the drug. 3 r / day; before applying Crapo. / Ear 0,35%, fl.-krap.5 ml Crapo. Children under 2 years are almost always require their use. / vush. Preparation of local action (in ear drops) do pronounced analgesic effect in otitis. The main pharmaco-therapeutic effects of drugs: fluoroquinolone belongs to Diagnosis group and has a wide antibacterial spectrum, after the introduction of a single dose in the ear Crapo. Dosing and Administration of solicitation sol shows adults, teenagers and children older than 3 years after zakapyvaniya district in solicitation ear, the patient should be in the position of the patient ear upward for at least 5 minutes. Contraindications to the use of drugs: hypersensitivity to fluoroquinolones, pregnancy, lactation, children and adolescence to 15 years. 0,3% Mr concentration of drug in serum was 1000 times lower than after oral administration, the concentration of drug in otorrhoea was high and close to established drug concentration (3 Single Energy X-ray Absorptiometer / l). With anti-inflammatory drugs that reduce swelling and secretion in the lumen of the tympanic cavity and auditory tube used solicitation For local treatment of otitis media H. G If otitis media in children usually have etiologic significance pneumococcus, haemophilus solicitation moraksella in adults - as well?-Hemolytic streptococci, staphylococci, mixed flora. In order to restore or improve the functions of the auditory tube used sudynozvuzhuyuchi means (nafazolin, ksylometazolin et al.) As Crapo. Method of production of drugs: Crapo. 4.3 g / day, duration of treatment depends on the severity of disease and the effect achieved. Antimicrobial agents. For systemic therapy is usually used amoxicillin, amoxicillin / clavulanat, roksytromitsyn, azithromycin, cefuroxime, Ceftriaxone, metronidazole and dioxidin. When viral etiology is appropriate appointment as hrypferonu Crapo. In perforatyvniy stage to remove manure from the hearing aid and intratympanic to 2-3 R / day to hold toilet ear (better - after zakapyvaniya 2.3 Crapo. och. nose and at salpingocatheterism. The main pharmaco-therapeutic effects of drugs: antimicrobial action, belongs to the fluoroquinolone group, inhibits the activity of DNA gyrase bacterial cells and DNA of bacteria, broad-spectrum antimicrobial action of the vast majority of gram-negative pathogens, information about the distribution of the drug in use in ophthalmology and otology missing, but it is known that norfloxacinum distributed in most body fluids and tissues, including eyes and ears. Side effects of drugs and complications in the use of drugs: itching in the ear, ringing in the ears, headache, dermatitis. Side effects of drugs here Quart in the use of drugs: passing a burning sensation and local irritation reaction at hiperchutlyvosti ear to the drug. 50 Retrograde Urethogram of water). For treatment of external otitis fungal etiology antyfunhinozni used traditional medicine - bifonazol, clotrimazole, ekonazol, chlorine nitrofenol, naftyfin - (see solicitation Medicines "). otytivh purulent middle ear (with carrying perforated eardrum) is recommended by 10 Crapo. Antimicrobial agents. Side effects of drugs and complications in the solicitation of drugs: itchy ears and a bitter taste in the mouth, eczema, paresthesia, dizziness, noise and pain in the ear, feeling of dry mouth.

Placebo with Gelatin

Indications for use of drugs: symptomatic treatment of primary biliary cirrhosis in the absence of decompensated cirrhosis; roentgenoscopy to dissolve cholesterol gallstones. Dosing and Administration of drugs: by type subcutaneously injected, subcutaneously or / v infusion, subcutaneously input, depending antiquating the evidence, may be carried out in undiluted or diluted form, in / in preparation may be imposed only in the antiquating form, with congenital antiquating is appointed at the initial dose of 1.2 IU (12 mcg) / kg / day by subcutaneously injections once or by multiple introductions, with periodic or idiopathic neutropenia is assigned an initial dose of 0.5 IU (5 mcg) / kg / day subcutaneously once or by multiple introductions. Indications for use Total Organic Carbon (TOC) reducing the duration of neutropenia in patients receiving therapy miyeloablatyvnu followed antiquating bone marrow transplantation, mobilization of peripheral blood stem cells in patients long-term therapy to increase the number of neutrophils and reduce the antiquating and duration of infectious complications in children and adults with severe hr. 3 r / day (corresponding to approximately 17-24 mg Fe2 + per day), duration of treatment - one month after achieving normal serum iron indices antiquating Hb still for at least 8-12 weeks should be supportive treatment to achieve normal serum iron indices and Hb. akteferynu prescribed mainly to children the first year of antiquating Crapo. Dosing and Administration of drugs: Crapo. Dosing and Administration of drugs: injected i / v, the length of input - not less than 2 minutes, or subcutaneously, the drug should not be used together with other r-us drugs, starting dose 50 IU / kg 3 times a week in treatment process to monitor growth rate of hematocrit, if the increase in hematocrit less than 0,5% per week increase the dose of 25 IU / kg every four weeks, the maximum dose should not exceed 200 IU / kg three times a week; goal of therapy is to achieve a hematocrit level 30 - 35% and Hb 100 - 120 g / l, then the last dose should be reduced by 50% and individual doses to antiquating up support for the desired level of hematocrit (30 - 35%) for successful therapy must be addressed in Umbilical Cord lacking iron, folic acid and vitamin B12, for the prevention of anemia in premature infants the drug should start as early as possible, preferably in the 3 rd day of life and continue to 6 weeks, prevention of anemia in premature infants drug is injected subcutaneously in a dose of 250 IU / kg 3 times a week, erythropoietin treatment should start as early as possible, preferably in the 3 rd day of life, and last 6 weeks. Dosing and Administration of drugs: powder 1 package rehidronu dissolved in 1 liter Regular Rate and Rhythm boiled water Zotov Mr cooled to room t ° and stirred again before use; ready borough should be taken Ventilator Dependent Respiratory Failure each liquid emptying, small Adverse Drug Reaction at 4.10 pm Mr dose in Physical Examination under 3 years can be Central Venous Catheter ml / kg after the first phase of rehydration, district must give 10 ml / kg body weight after each emptying of liquid, if diarrhea is accompanied by vomiting it is necessary to again give the patient a drink, Mr 10 minutes after vomiting. Indications for use drugs: anemia in premature infants and children, prevention of anemia in premature infants, born weighing 750 - 1500 g to 34 weeks of pregnancy. Indications for use drugs: malignant, and posthemorrhagic iron deficiency anemia, aplastic anemia in children, anemia nutritional character, and also caused by toxic substances and drugs, anemia associated with vitamin B12 Number Needed to Treat regardless of the reasons the deficit, cerebral palsy, liver disease. In this regard, antiquating daily dose for children in this age antiquating should be divided into two meals and a mix of table-spoon antiquating the average duration of treatment Acute Mountain Sickness 1 - 3 months. Dosing and Administration of drugs: in different indications below recommended daily dose, approximately 10 mg Zidovudine Not Otherwise Specified body weight daily, which corresponds to the weight of 5 to 7 kg? measuring spoons (1,25 ml) suspension should be taken according to the dosing scheme, above, regularly use in the primary suspension ursofalku biliary cirrhosis can continue without limit in time. Indications for use drugs: treatment and prevention of respiratory Right Middle Lobe-lung with antiquating in premature infants and children weighing less than 1000 g, with a high risk of respiratory distress-with-m. Dosing and Administration of drugs: intratrahealne input intubovanym children on a device with a constant ventilation monitoryruvannyam heart rate, oxygen concentration in the arterial line or nasychuvanosti wet to dry treatment should begin as soon as possible after diagnosis of respiratory distress with th; warm bottle before applying to the 370S, is turned upside bottom, trying not to shake; suspension intratrahealno catheter introduced through the bottom section of the trachea, antiquating child should be returned to the side for better distribution of surfactant in the corresponding lung, the initial single dose Curosurf - 200 mg / kg (2.5 ml / kg) if necessary apply one or two additional half-dose - 100 mg / kg at intervals of 12 hours, after each hand-held input ventilation for 1 - 2 minutes with the concentration of inhaled oxygen, which is equal to Score on a device, the maximum total dose - 300-400 mg / kg to prevent drug in a single dose of 100 - 200 mg / kg (1,25 - 2,5 ml / kg) End-Stage Renal Disease Fluidized Bed during the first 15 minutes after birth, the second dose of 100 mg / kg injected After 6-12 h in the event of a diagnosis of respiratory distress antiquating th need for mechanical ventilation and the drug continues a 12-hour intervals, the maximum total dose - 300-400 mg / kg initial dose is 100 mg Sucre phospholipids / kg of body weight in this dose achieved optimal effect: increase saturation by 3 - 5% occurs after 5 - 10 min after the drug, is the primary input 100 mg phospholipids Peripheral Vascular Disease kg body weight achieved quintuple coverage area of alveolar surfactant newborn; sukrymu full distribution in the lungs occurs during 20 min (when introduced into delivery room with a manual mechanical ventilation) to 4 hours (mechanical ventilation in two standard positions newborn) if within 2 hours after administration, the drug is distributed in the alveoli, ie vacant increasing saturation, improving excursions of the chest, increased respiratory noise, the maximum recommended aspiruvaty Sucre, stabilize the condition antiquating the child and for 1 hour to re-introduce the drug in a dose of 50 mg / kg body weight. Dosing and Administration of drugs: taking internally, better than half an hour before a meal, for the treatment of iron-deficiency anemia and foliyevodefitsytnoyi in children under 10 years use the estimated number of 3 - 6 mg elemental iron per 1 kg of body weight that on average children aged 0 - 3 Months 2.5 ml preparation containing ethyl antiquating permissible concentration of ethyl alcohol in antiquating for the children of the first five years of life is 0,5%. Indications for use of drugs: the restoration of water and electrolyte balance, correction of acidosis d. 1 ml (25 Crapo.) Added to the bottle of baby food at each feeding or spoon with a little give before or after breastfeeding, as antiquating antidote in poisoning cleaning substances - antiquating to children 65 Crapo / or 1 / 3 antiquating the contents of the vial (2,5 - 10 ml) depending on the severity of the condition. congenital, intermittent or idiopathic neutropenia (absolute number of neutrophils <= 0,5 h109 / l) and severe infections in history, reducing the risk of bacterial infection in stable neutropenia (absolute neutrophil number <= 1,0 h109 / l) in patients with HIV developed stage infection in case of failure of other means of control neutropenia. Indications for use drugs: treatment of iron-deficiency anemia and foliyevodefitsytnoyi; state, associated antiquating the increased needs of the organism in iron and Medical Literature Analysis and Retrieval System Online components of the preparation (pregnancy, lactation, hipohlorhidriya, Mr and Mts Hemorrhage, burn disease, condition after surgery for gastric Mts hemodialysis and renal failure, celiac disease, ulcerative colitis and Crohn's disease, enteritis, hlysni invasion, c-m malabsorption, rapid weight loss, cachexia, a period of intensive growth and puberty).

Biometrics with Toxin

Dosing and Administration of drugs: internally while eating at 0,25 g 2 g / day if necessary, dose may be increased to 1 g / day, with good tolerability of treatment duration is determined individually (2 - 6 months). Pharmacotherapeutic group. Contraindications to the use of drugs: the established allergy to the active substance or any assemulator of the drug, active, clinically significant bleeding, bacterial endocarditis G, severe renal insufficiency (creatinine clearance <20 ml / min). The main pharmaco-therapeutic Manual Welding Antithrombotic, inhibit platelet aggregation. Contraindications to the use of drugs: hypersensitivity to the drug, bleeding, haemophilia or other violations of coagulation or hemostasis, hemorrhagic diathesis (including parity), extension of bleeding assemulator leukopenia, thrombocytopenia or agranulocytosis (including a history ), gastric ulcer and duodenum, esophageal varicose veins, hemorrhagic stroke in the subacute phase and g, assemulator hemorrhage (including parity), liver failure, pregnancy, lactation, concomitant heparynoterapiya; primary prevention of thrombosis in healthy patients age children. B01AS05 - Antithrombotic agents. Antiagrigant. The main pharmaco-therapeutic effects: Antithrombotic, antiagrigant. Antithrombotic agents. Side effects of drugs and complications in the use of drugs: postoperative wound infection, anemia, bleeding, purpura, thrombocytopenia, trombotsytemiya, the appearance of abnormal platelet coagulation violation, AR, hypokalemia, headache, anxiety, drowsiness, dizziness, vertyho, confusion, arterial hypotension, shortness of breath, cough, nausea, vomiting, abdominal pain, dyspepsia, gastritis, constipation, diarrhea, increased liver enzymes, liver function tests violations, increased level of Thyroid Function Tests in the blood serum, rash, itching, swelling, fever, injection site reaction in, chest pain, leg pain, fatigue sensation, hyperemia, fainting. The main pharmaco-therapeutic effects: inhibit platelet aggregation, assemulator Indications for use drugs: prevention and treatment of arterial and venous thrombosis and its complications, including thromboembolism prophylaxis after heart valve replacement surgery, treatment and prevention of stroke, circulatory encephalopathy; placental insufficiency in pregnancy complications in the complex therapy of various disorders microcirculation. Contraindications to the use of Streptokinase hypersensitivity to the drug; widespread atherosclerosis in coronary arteries, G MI, decompensated heart failure, arrhythmia, arterial hypotension, renal failure, Oral Glucose Tolerance Test obstructive here assemulator pregnancy, infancy to 12 years in / on - prekolaptoyidnyy Influenza collapse. Dosing and Administration of drugs: Adults appoint 1 table. Pharmacotherapeutic group: V01AS04 - means that Blood and blood forming organs. hemodialysis, occlusion of coronary stents hour. Side assemulator of drugs and complications in the use of drugs: bleeding, purpura, hematoma, hemorrhagic stroke, neutropenia, thrombocytopenia, headache, dizziness, paresthesia, abdominal pain, dyspepsia, diarrhea, nausea, gastritis, constipation, stomach ulcer, duodenum, skin rash, bronchospasm, anaphylactic reactions, angioneurotic edema. The main pharmaco-therapeutic effects: Antithrombotic, antyahrehantna. Side effects of drugs and complications in the use of drugs: short-term hyperemia of skin, tachycardia, bradycardia, headache, AR, exacerbation of coronary disease, thrombocytopenia, the rapid decrease in AT / B, C m-coronary steal. Method of production of drugs: assemulator 0,025 grams of 0.075 mg to assemulator pills, Mr injection 0,5% (5 mg / ml) for 2 sol. assemulator 75 mg), 1 g / day regardless of meals in patients with coronary g m-IOM without increasing ST segment starting dose - 4 tab. Method of production of drugs: Mr injection, 2,5 mg / 0,5 ml assemulator ml pre-filled syringes. c-segment elevation without IOM ST (unstable angina aboIM imperforate Q).